Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Jon Kindblom

Physician

Jon Kindblom
Physician
MD, PhD
jon.kindblom@medic.gu.se
+46 31-342 1000

Postal Address: Jubileumskliniken, Sahlgrenska universitetssjukhuset, 413 45 Göteborg
Visiting Address: Jubileumskliniken, Sahlgrenska universitetssjukhuset, Blå stråket 2 , Göteborg


Department of Oncology at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
0313428503
Visiting Address: Blå stråket 2 SU/Jubileusklin , 413 45 Göteborg

Latest publications

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”
A. Widmark, A. Gunnlaugsson, L. Beckman, C. Thellenberg-Karlsson, M. Hoyer et al.
International Journal of Radiation Oncology, Biology, Physics, 96 (5), s. 938–939, Conference paper 2016
Conference paper

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan et al.
The New England journal of medicine, Journal article 2013
Journal article

Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Kuo-Pao Lai, Chiung-Kuei Huang, Lei-Ya Fang, Kouji Izumi, Chi-Wen Lo et al.
Molecular endocrinology (Baltimore, Md.), Journal article 2013
Journal article

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.
Åsa Jellvert, Ingela Frank-Lissbrant, Maliha Edgren, Elisabeth Ovferholm, Karin Braide et al.
Experimental and therapeutic medicine, Journal article 2011
Journal article

Showing 1 - 10 of 16

2019

2016

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”
A. Widmark, A. Gunnlaugsson, L. Beckman, C. Thellenberg-Karlsson, M. Hoyer et al.
International Journal of Radiation Oncology, Biology, Physics, 96 (5), s. 938–939, Conference paper 2016
Conference paper

2014

2013

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan et al.
The New England journal of medicine, Journal article 2013
Journal article

Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Kuo-Pao Lai, Chiung-Kuei Huang, Lei-Ya Fang, Kouji Izumi, Chi-Wen Lo et al.
Molecular endocrinology (Baltimore, Md.), Journal article 2013
Journal article

2011

Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.
Åsa Jellvert, Ingela Frank-Lissbrant, Maliha Edgren, Elisabeth Ovferholm, Karin Braide et al.
Experimental and therapeutic medicine, Journal article 2011
Journal article

Showing 1 - 10 of 16

Page Manager: Katarina Olinder Eriksson|Last update: 3/28/2013
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?